1.1Poloxamer stabilizes the suspension
The hydrophobic block of poloxamer 188 adsorbs to the drug particle surface. Its hydrated outer blocks form a steric barrier that limits particle aggregation in water.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The hydrophobic block of poloxamer 188 adsorbs to the drug particle surface. Its hydrated outer blocks form a steric barrier that limits particle aggregation in water.
Hydroxypropyl beta-cyclodextrin associates reversibly with hydrophobic portions of the drug through its internal cavity. This association increases the total dissolved drug concentration by holding part of the drug in complexed form.
Spray drying a solution of the drug and copovidone produces a solid dispersion. The polymer reduces molecular mobility in the dry powder and slows crystal growth during storage.
High-shear mixing distributes micronized drug particles in water containing hydrated hydroxypropyl methylcellulose. The higher viscosity slows sedimentation, and shaking redistributes particles that settle.
Controlled crystallization isolates the neutral compound as a solid. Milling controls the particle size, and polysorbate 80 promotes wetting when the particles are dispersed in water.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A laboratory instrument test set contains sealed optical cells filled with the aqueous isoquinolinone suspension and a blank cell filled with the polysorbate 80 vehicle. The instrument measures the blank before recording transmitted light through the suspension at a fixed height. A fixture inverts each suspension cell before measurement, and timed readings track the change in optical signal as particles settle.
Poloxamer 188 replaces polysorbate 80 as the nonionic wetting agent in the aqueous isoquinolinone suspension. The poloxamer dissolves in the aqueous vehicle before stirring incorporates the active ingredient particles. Its hydrophobic blocks associate with particle surfaces, and its hydrophilic blocks extend into the aqueous phase to limit aggregation.
A filling line dispenses the same isoquinolinone and polysorbate 80 suspension into identical 10 mL glass vials at fill volumes of 2 mL, 5 mL and 8 mL. The line closes all vials with the same stopper and crimp seal. After storage, a vial inverter runs at 20 revolutions per minute, and the operator counts the revolutions needed to lift visible sediment from the vial base.
A sanitary sampling loop connects the lower outlet of a stirred holding vessel to a return port below the liquid surface. A peristaltic pump circulates the isoquinolinone suspension through the loop while the vessel agitator keeps particles dispersed. A valve diverts a sample into a collection vial after three loop volumes have circulated.
A dual chamber vial stores a freeze-dried preparation of the isoquinolinone active ingredient, polysorbate 80 and trehalose in one chamber and an aqueous diluent in the other. A movable stopper separates the chambers and opens a bypass when the operator presses the actuator. The diluent flows through the bypass, and inversion rehydrates the dry preparation and disperses the active ingredient before withdrawal.
A holding vessel contains the aqueous isoquinolinone suspension with polysorbate 80 and feeds a vial filler through a recirculating line. Optical backscatter probes at two heights in the vessel measure differences in suspended solids. A controller adjusts agitator speed and enables filling after the difference between probe readings stays below a preset threshold for a specified interval.
Hydrochloric acid protonates a basic site on the compound in solution. Controlled crystallization isolates the hydrochloride salt, and the dried solid is blended with a polysorbate 80-containing excipient premix.
Polysorbate 80 is dissolved in a portion of the formulation water, and the drug powder is added under agitation to form a slurry. The slurry is diluted with the remaining vehicle and mixed until the particles are uniformly dispersed.
patent.fyi, US 2026/0355201 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355201/, SHA-256 27cc3f97654081a73859ecdc678abfd6520a1a1d957348359180a4db47c2cd89